Home / Clinical Decision Support & Reference / IRIS INTELLIGENT RETINAL IMAGING

IRIS INTELLIGENT RETINAL IMAGING

by INTELLIGENT RETINAL IMAGING SYSTEMS · Based in United States → — Ending preventable blindness through accessible, point-of-care diabetic eye exams.

Endocrinology Internal Medicine Ophthalmology

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Contact for pricing

Regulatory Status Disclosed

Overview

Intelligent Retinal Imaging Systems (IRIS) provides a cloud-based teleretinal screening platform designed to combat preventable blindness, primarily focusing on diabetic retinopathy. The IRIS solution is camera-agnostic, allowing integration with various fundus cameras, including both stationary and portable models. It enables healthcare providers, including primary care physicians, Federally Qualified Health Centers, and larger health systems, to conduct quick (typically under 5-10 minutes) and non-dilated retinal exams at the point of care.

The platform utilizes proprietary image capture and enhancement technology to ensure high-quality retinal images, which are then securely uploaded to the cloud. These images are reviewed remotely by a network of board-certified retina specialists and ophthalmologists at the IRIS Reading Center (IRC) or a local eye care provider. The system also incorporates AI-assisted diagnostics to enhance ocular images and highlight potential areas of pathology, aiding specialists in making diagnoses. Detailed, easy-to-understand patient reports are generated and returned securely to the provider’s EMR/EHR within one business day, along with referral recommendations if needed.

IRIS aims to improve quality scores (like HEDIS and Star ratings) and close care gaps by increasing access to preventative eye care, especially for underserved populations. The company provides comprehensive support, including on-site and virtual training for staff, to ensure seamless integration into existing clinical workflows.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

Cloud-based teleretinal screening platform
Camera-agnostic solution
AI-assisted diagnostics and image enhancement
Remote reading by board-certified specialists (IRIS Reading Center)
Seamless EMR/EHR integration
Detailed patient reports and referral recommendations
On-site and virtual staff training provided
Secure cloud computing and data storage
Supports non-mydriatic fundus cameras
Real-time image reading and classification following AAO criteria

Use Cases

Diabetic retinopathy screening at point-of-care
Screening for macular edema and glaucoma
Improving HEDIS and Star ratings for healthcare organizations
Increasing access to preventative eye care for underserved populations
Facilitating timely referrals to eye care specialists
Early detection of other eye conditions

What Physicians Need to Know

Evidence Base

IRIS is an FDA Class II cleared cloud-based platform primarily focused on screening for vision-threatening Diabetic Retinopathy (DR). Research indicates that early detection through retinal screening can prevent over 90% of DR cases. The platform's efficacy is supported by scientific literature, including a study published in the *Diabetes Research and Clinical Practice* journal. Beyond DR, the system, through its human graders, also supports the detection of macular edema, glaucoma, and age-related macular degeneration (AMD).

Clinical Validation Studies

A multicenter, retrospective chart review utilizing IRIS screening data from over 5,000 patients (10,223 eyes) demonstrated the platform's effectiveness in identifying DR (33.98%) and Diabetic Macular Edema (DME) (4.31%), with prevalence rates correlating significantly with epidemiological factors like DM incidence. The system boasts a high average image gradability rate of 95% for its clients, which is critical for accurate diagnosis, and a reported sensitivity rate of 97%.

Alert Fatigue Management

IRIS employs a human-in-the-loop model, leveraging a team of 120+ board-certified physicians at the IRIS Reading Center (IRC) to review and interpret retinal images. This approach inherently mitigates alert fatigue by providing nuanced diagnoses and identifying 'suspected' conditions beyond simple refer/no-refer flags, offering more comprehensive insights.

Override Rate Data

Specific override rate data is not explicitly provided, as the system's diagnostic process relies on the expert interpretation of IRC physicians rather than an autonomous AI decision that would be subject to override. The human grader provides the definitive diagnosis.

Differential Diagnosis Support

IRC physicians provide diagnoses for various stages of diabetic retinopathy and macular edema. They can also identify and notate other 'suspected' conditions, including glaucoma, age-related macular degeneration (wet/dry AMD), tumors, and melanoma, offering broader diagnostic insights. Future developments aim to expand the utility of ocular data for early detection of cardiovascular disease, chronic kidney disease, and Alzheimer's disease.

Guideline Update Frequency

As an FDA Class II cleared medical system, IRIS adheres to regulatory standards and follows American Academy of Ophthalmology classification criteria for grading. While a specific update frequency for guidelines isn't detailed, the platform's cloud-based nature and ongoing development, particularly following its acquisition by Topcon Healthcare, suggest continuous refinement and adherence to current medical standards and best practices.

Clinical Workflow Integration

IRIS is designed for seamless integration with both popular and custom EHR/EMR systems. It utilizes HL7 messages for content exchange and an IRIS EMR Proxy application for secure integration with on-premise systems. The workflow involves a quick 5-minute screening, secure image upload to the cloud-based platform, proprietary image enhancement, remote review by a licensed physician, and results returned to the EHR/EMR within two business days. Comprehensive on-site and virtual staff training is provided to ensure smooth implementation.

Decision Audit Trail

The system securely stores and manages patient data, diagnostic data, and images. Diagnostic reports and retinal images are automatically documented within the patient's electronic health record, creating a comprehensive and longitudinal record of eye health over time.

Physician Tip

Leverage IRIS for efficient, early detection of diabetic retinopathy and other retinal pathologies directly within your primary care setting, significantly improving patient outcomes and HEDIS compliance. The human-centered interpretation by board-certified specialists ensures nuanced diagnoses, including the identification of 'suspected' conditions beyond DR. Seamless EHR integration streamlines your workflow, making retinal screenings a routine part of diabetic patient care without disruption. Utilize the provided training and ongoing support to maximize the system's benefits and enhance patient engagement in preventative eye care.

IRIS offers robust integration capabilities with a wide range of EHR/EMR systems, including popular and custom platforms. It supports secure data exchange via HL7 messages and utilizes an IRIS EMR Proxy for on-premise system integration. The solution is camera-agnostic, allowing flexibility with various fundus cameras, and operates on a secure, cloud-based platform for efficient image management and diagnostic reporting.

At a glance

Pricing Contact for pricing

Deployment Cloud Based, Web Based

Visit site

Details

Category	Clinical Decision Support & Reference, Ophthalmology AI
Pricing	Contact for pricing — Contact for pricing
Deployment	Cloud-based, Web-based
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	1 AI-estimated The IRIS Intelligent Retinal Imaging Systems received FDA clearance in 2015 as a Class II medical device. It is a comprehensive web-based software system intended for storing, managing, and displaying patient data, diagnostic data, and images from computerized diagnostic instruments for screening diabetic retinopathy, macular edema, glaucoma, and other suspected conditions.
Integrations
EHR	Not specified
Specialties	Endocrinology, Internal Medicine, Ophthalmology

What the Web Says

IRIS Intelligent Retinal Imaging is generally well-regarded by physicians for its ease of use, efficiency in workflow, and ability to provide early detection of retinal diseases. Healthcare IT and tech reviewers often highlight its cloud-based platform and integration capabilities with EHR systems, though some express concerns about data security and the learning curve for new users. Reddit, G2, and Capterra reviews echo these sentiments, emphasizing the benefits for patient care and practice management.

Overall: Positive

Strengths

Improved patient compliance for diabetic retinopathy screenings.
Enhanced workflow efficiency and reduced administrative burden.
Early detection of retinal diseases, leading to better patient outcomes.
Cloud-based platform with good EHR integration.
User-friendly interface for clinical staff.
Reduces the need for patient referrals to specialists.

Limitations

Initial setup and integration can be complex and time-consuming.
Potential concerns regarding data privacy and security with cloud storage.
Requires dedicated training for staff to optimize usage.
Cost of implementation and ongoing subscriptions can be a barrier for smaller practices.
Reliance on internet connectivity for cloud-based features.
Some users report occasional software glitches or slow performance.

Based on reviews from: Physician reviews (various medical forums), Healthcare IT publications, Tech review sites, Reddit, G2, Capterra

Last updated: 2026-07-21

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate IRIS INTELLIGENT RETINAL IMAGING

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

Press & Coverage

IRIS retinal screening (Press Release)

Topcon Healthcare Acquires Intelligent Retinal Imaging Systems to Enhance Connected Care Across Primary and Eye Care

Topcon Healthcare, a leader in digital health and ocular data solutions, acquired Intelligent Retinal Imaging Systems (IRIS) to expand its presence in primary care and reinforce its commitment to early disease detection. The acquisition aims to enhance coordination between primary care providers and eye care professionals, leveraging AI-analyzed ocular data to detect systemic or neurological diseases.

2025-07

PR Newswire

IRIS Reaches 1 Million Lives

Intelligent Retinal Imaging Systems (IRIS) announced a significant milestone of performing one million diabetic retinal exams since June 2013, with 130,000 of these exams identifying sight-threatening pathology. This achievement underscores IRIS's mission to end preventable blindness by increasing access to annual diabetic retinal exams.

2023-05

IRIS retinal screening (Press Release)

IRIS Expands AI Partnerships with Thirona Retina BV

IRIS partnered with Thirona Retina BV to license its CE (0344) certified RetCADu2122 software for international markets, enabling IRIS customers to use AI for detecting diabetic retinopathy, glaucoma, and age-related macular degeneration. This collaboration aims to process more patient cases faster and with greater accuracy.

2023-08

PR Newswire

HealPros & IRIS Optimize In-Home Retinal Screenings

IRIS partnered with HealPros to optimize in-home diabetic retinal screenings for individuals with chronic illnesses, aiming to improve early diagnosis and prevention of diabetic retinopathy. This collaboration leverages IRIS's FDA Class II cleared cloud-based platform and HealPros' in-home healthcare services.

2022-08

Quest Diagnostics (Press Release)

Quest Diagnostics Adds Diabetic Retinopathy Screening Through its Patient Service Centers in Collaboration with IRIS

Quest Diagnostics announced a collaboration with IRIS to offer diabetic retinal imaging services at designated Quest patient service centers across the U.S. This initiative aims to increase convenience and improve screening rates for diabetic retinopathy, a leading cause of blindness.

2022-04

JMIR Formative Research

Colocating Teleophthalmology Within Primary Care Settings to Improve Access to Diabetic Retinopathy Screening: Retrospective Descriptive Evaluation

A retrospective study evaluated the effectiveness of a telemedicine platform using specialized IRIS cameras in primary care settings to increase diabetic retinopathy screening rates. The study found that the IRIS platform, which is FDA-approved for diagnosing diabetic retinopathy and macular edema, yielded high sensitivity and a low false-negative rate.

2022-10

CollaborativeEYE

The Role of Artificial Intelligence in Detecting Diabetic Retinopathy

This article discusses the role of AI in detecting diabetic retinopathy, highlighting IRIS (Intelligent Retinal Imaging Systems) as an FDA class 2 retinal diagnostic solution. It notes IRIS's integration into primary care workflows to identify early diabetes and reduce healthcare costs, including a 2019 partnership with Remidio Innovative Solutions.

2021-01

Biomedix (Press Release)

IRIS (Intelligent Retinal Imaging Systems) and Biomedix Sign Strategic Partnership Agreement

IRIS and Biomedix announced a strategic partnership to integrate diabetic retinopathy examinations into the Biomedix Xchange Population Health Management Solution. This collaboration aims to optimize HEDIS measures, boost Star ratings, and enable cost-effective care delivery for diabetic patients.

2021-02

Videos

Product demos, reviews, and walkthroughs for IRIS INTELLIGENT RETINAL IMAGING.

Intelligent Retinal Imaging Systems - Job Creation in Pensacola, Fl

IRIS

ABC 13 News: IRIS Screening for Diabetic Retinopathy at Harris Health System

IRIS

Saving Sight: An IRIS & CoxHealth Story

IRIS

Diabetic Retinopathy - Early Detection with IRIS

IRIS

IRIS Named Microsoft AI for Health Grantee

IRIS

Telemedicine for Detecting Diabetic Retinopathy - Part One

IRIS

View all on YouTube

Frequently Asked Questions

How does IRIS Intelligent Retinal Imaging integrate into a primary care physician's workflow, and what retinal conditions can it help screen for?

IRIS integrates by allowing healthcare providers to capture digital retinal images using various fundus cameras, which are then securely uploaded to the IRIS platform. These images are enhanced and reviewed remotely by licensed eye care professionals at the IRIS Reading Center, enabling screening for diabetic retinopathy, macular edema, glaucoma, and other suspected conditions.

What regulatory clearances does IRIS Intelligent Retinal Imaging hold, and how does it ensure patient data privacy and security?

IRIS is an FDA-cleared Class II medical system for screening vision-threatening diabetic retinopathy, macular edema, glaucoma, and other suspected conditions. The platform securely uploads images to the cloud, and while AI technologies could reidentify biometric information, care is taken when collecting and processing images to balance data privacy and transparency.

What are the specific limitations of the AI component within IRIS, and how does the involvement of human graders mitigate these?

While AI can rapidly detect potential diseases, autonomous AI solutions may not define the specific stage of retinopathy or identify other suspected conditions beyond diabetic retinopathy. IRIS addresses this by utilizing a network of board-certified ophthalmologists and retina specialists in its Reading Center who grade exams, diagnose all stages of diabetic retinopathy and macular edema, and notate additional suspected conditions.

How does IRIS differentiate itself from fully autonomous AI diagnostic systems or traditional referral pathways to ophthalmologists?

Unlike fully autonomous AI systems that provide instant but less specific diagnoses, IRIS combines AI-assisted diagnostics with human interpretation from a network of board-certified specialists. This hybrid approach aims to provide more accurate and specific diagnoses, identify a broader range of pathologies, and facilitate timely referrals, bridging the gap between primary care and specialized eye care.

What are the typical cost considerations for a physician's practice looking to implement IRIS Intelligent Retinal Imaging, particularly regarding necessary equipment?

IRIS software is camera-agnostic and can be utilized with various fundus cameras, ranging in price and portability. Handheld fundus cameras, which are portable and less expensive, start around $16,000, offering a more affordable entry point compared to tabletop cameras, though specific IRIS service pricing is not detailed.

What is the reported accuracy and image interpretation success rate of the IRIS platform?

IRIS has reported a sensitivity rate of 97% for detecting potential pathology and continuously refines its algorithms. Historically, its success rate for images able to be interpreted remotely is 93-94%, ensuring high-quality images are reviewed for diagnosis.

How does IRIS address ethical concerns related to AI in healthcare, such as algorithmic bias and legal liability?

IRIS acknowledges the importance of ethical considerations, including potential algorithmic biases and the need for clear legal liability. While AI assists in diagnosis, the ultimate responsibility for patient care and diagnosis rests with the healthcare provider, supported by IRIS's human graders.